Editorial: novel biomarkers for anticancer therapy

HIGHLIGHTS

• who: . and colleagues from the Fudan University, China have published the paper: Editorial: Novel biomarkers for anticancer therapy, in the Journal: (JOURNAL) of 21/01/2022
• future: Nine hub genes which may modulate NSCLC progression and cisplatin resistance were identified by Mengyan et_al but more experiments are needed to verify their conclusion. Yan et_al performed a metabolomics analysis in NSCLC patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) or PD-1/PD-L1 inhibitors and found that EGFR-TKIs and PD-1/PDL1 inhibitors could promote lipid and amino_acid metabolism alterations providing . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.